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Abstract
Back ground: Primary small cell carcinoma of the pancreas (SCCP) is a rare malignancy with an extremely poor
prognosis which accounts for 1 to 1.4 percent of all pancreatic malignancies.
Case presentation: We present the case of a 62-year-old man with a half-month history of upper abdominal
discomfort who was diagnosed with SCC of the pancreatic tail. A Chest X-ray showed no evidence of primary lung
tumor. The diagnosis of a SCCP was confirmed by post-surgery pathology and immunohistology. In our review of
the published reports of SCCP, we only found a few cases reported in the literatures. The diagnosis of SCCP needs
the post-surgery pathology and immunohistology and the prognosis of SCCP is extremely poor. There was a
significant increase in median survival, from 1 to 6 months, in treated patients compared to patients treated only
by symptomatic management. Chemotherapy was the most common treatment and the combination of cisplatin/
etoposide was most frequently prescribed.
Conclusion: The accurate diagnosis of (SCCP) is necessary for determining prognosis and deciding appropriate
therapy.
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Background
Small cell carcinomas (SCCs) is an aggressive tumor,
which account for 18-20% of all primary lung cancers,
but they are also described in the urinary bladder, pros-
tate, salivary glands, pharynx ,l a r y n x ,e s o p h a g u s ,s t o -
mach, pancreas, colon, rectum, skin, and cervix [1-3].
Similar to SCC of the lung, SCC of the pancreas (SCCP)
is a lethal disease and its prognosis is extremely poor. If
untreated, it progresses rapidly with fatal course. We
hereby reported a case of SCCP and reviewed the arti-
cles associated with the SCCP.
Case presentation
The patient was a 62-year-old man. Except hyperten-
sion, he had no significant past medical history. He
went to our hospital on July 21, 2011, with the symptom
of upper abdominal discomfort. The local hospital CT
scan revealed a low-density mass at the pancreatic tail
(Figure 1). Laboratory examination: Hemoglobin: 149 g/
L; white blood cell count: 4.7 × 10
9/L; platelets: 78 ×
10
9/L; AST: 21 U/L; ALT: 14 U/L; total bilirubin: 14.2
μmol/L; direct bilirubin: 6.6 μmol/L; serum creatinine:
75 μmol/L;AFP:2.2 ng/mL (normal < 20 ng/ml); CA19-
9:122.7 U/mL (normal < 37 U/mL); CEA: 2.82 ng/ml
(normal < 5 ng/mL). Chest X-ray had no sign of pri-
mary lung cancer and metastasizes. In addition, there
was no evidence of ascites, and liver metastasizes; there-
fore exploratory laparotomy was performed routinely.
At abdominal exploration, a 6 cm mass was found in
the pancreatic tail. So we performed distal pancreatect-
omy with splenectomy. All pathology specimens were
routinely processed. Histological examination showed
spindle-shaped cells with scanty cytoplasm and hyper-
chromatic nuclei (Figure 2A). Metastasis cells were found
in the left adrenal (Figure 2B). Immunohistochemical
stains were performed on the paraffin-embedded
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to neuron-specific enolase (NSE) and chromogranin A
(Figure 3). The patient was discharged on postoperative
day15 in stable condition. The patient is followed up and
currently performing chemotherapy.
Discussion
SCCP is a rare neoplasm, with only a few cases reported
in the literatures (Table 1). Among all the primary pan-
creatic neoplasms, only 1% neoplasms are SCCP [4].
Preoperatively, it is difficult to distinguish SCCP from
pancreatic adenocarcinoma by imaging studies. How-
ever, some studies have indicated that imaging studies
might be helpful in the differential diagnosis of SCCs of
the pancreas [5,6]. In 2000 Ichikawa et al. [5] reported
three cases of SCCP. In each case, the tumor arose from
the head of the pancreas as a large (size 5-7 cm), homo-
geneous mass by noncontrast CT. Furthermore, all the
tumors showed minimal contrast after intravenous con-
trast injection. Although pulmonary SCC was frequently
associated with paraendocrine syndromes; extrapulmon-
ary SCC does not accompanied with identifiable para-
neoplastic syndromes frequently. Only two reported that
SCCP had elevated hormones levels: one with adreno-
corticotrophic hormone (ACTH) secretion [7] and the
other with paraneoplasic hypercalcemia [8]. Neuron-spe-
cific enolase (NSE), which is found in neuroendocrine
cells, is a good marker for the diagnosis of pulmonary
SCC [9,10]. Furthermore, Johnson et al. [10] reported
that serum NSE concentrations correlated with the
extent of the disease and response to treatment. In
other reported cases, NSE was increased also in SCCP
[11,12]. Therefore NSE could be considered as a tumor
marker and could be used for diagnosis or assessment
of treatment effect in patients with SCCP [12,13]. In our
case, we checked the serum NSE post-surgery (20.9 ng/
ml) which was still above normal level (< 15.2 ng/ml).
Nakamura et al [12] reported that serum carcinoem-
bryonic antigen (CEA) concentrations might also be
used for assessment of treatment effect but not good for
the differential diagnosis, because the presence of a high
CEA concentration in patients with SCCP is variable (in
our case, the serum CEA was normal) and CEA is not
specific for SCCP but also frequently increases in patient
with pancreatic ductal adenocarcinoma. Pro-GRP is
known to be more stable than GRP and is more sensi-
tive and specific tumor marker than NSE in pulmonary
SCC [14] and also in extrapulmonary SCC [15]. Matsu-
bayashi et al [11] suggests that Pro-GRP could also be
an important marker for diagnosis and assessment of
treatment in patients with SCCP.
In a review of all published cases of SCCP, 91% have
metastasizes at the time of initial diagnosis. In Bertrand
et al report, the most frequent sites of metastasis are the
peripancreatic lymph nodes (62%), the liver (38%), the
lungs (14%), the bone marrow (14%), the bone (10%),
the colon (10%), and the adrenal gland (10%); rarer sites
included the spleen, gallbladder, kidney, skin and brain
[16]. In our case, the SCCP had metastasizes in the left
adrenal gland. Therefore the majority of patients had no
opportunity for their tumor-resection. Until now only
few cases had the tumor-resection. Winter et al [6]
reported 6 cases SCCP who had the surgery. These
patients were followed with adjuvant chemoradiother-
apy. Three of six patients survived more than 2 years,
and two patients survived over five years. The patient
AB
Figure 1 Computed tomography (CT) scan of the upper
abdomen. There was a homogeneous mass in the pancreatic body
and tail by noncontrast CT scan (A). In the arterial phase the mass
was in low density (B).
AB
Figure 2 Histology of the SCCP. HE stains demonstrated the small
cell character of the SCCP. There are nests of small to medium-sized
cells with scanty cytoplasm and hyperchromatic nuclei (A, ×200).
Metastasis was found in the adrenal gland (B, ×200).
AB
Figure 3 Immunohistochemistry of the SCCP. The tumor cells
were positive for NSE (× 200, Figure 3A) and Chromogranin A (×
200, Figure 3B).
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reported survival for pancreatic SCC to date. The med-
ian survival was 20 months, which is comparable to
patients with resected ductal adenocarcinoma of the
pancreas [17]. Their research makes us believe that
combined surgery with adjuvant chemoradiotherapy
might improve the prognosis of SCCP.
As for the pulmonary SCC, the encouraging long
remission rates could be achieved by chemotherapy
and/or radiation. Surgery alone is generally unsuccess-
ful in managing either pulmonary or extrapulmonary
SCC [16]. Because the combination of cisplatin/etopo-
side is most frequently prescribed in SCCP, this com-
bination is also widely used in SCCP. In 1989, Morant
et al [18] reported complete remission of refractory
SCCP with cisplatin and etoposide. Initial chemother-
apy with streptozotocin, 5-fluorouracil, and methotrex-
ate, doxorubicin, cyclophosphamide, and lomustine
(MACC) had been unsuccessful. They used a schedule
consisting of etoposide and cisplatin which made the
patient remain in complete remission 50 months after
the diagnosis. Sakamoto et al [19] diagnosed 4 cases of
SCCP with endoscopic ultrasonography-guided fine-
needle aspiration (EUS-FNA). All patients were treated
with combination chemotherapy using a schedule con-
sisting of carboplatin and etoposide. Three patients
treated with the combination chemotherapy achieved
remission, two with a complete response and one with
a partial response. The remaining one patient showed
no change. One of the two patients with a complete
response survived for 56 months following the
diagnosis. Recently, Berkel et al [20] demonstrated that
local tumor control could be achieved with gemcita-
bine once a week and a long-acting somatostatin ana-
logue once a month; however, liver metastasis in their
p a t i e n ts h o w e dp r o g r e s s i o n .B e r t r a n de ta l[ 1 6 ]m a d ea
review on the SCCP. In their report, patients receiving
either systemic or local therapy showed a significantly
higher median survival compared to patients treated
with symptomatic management alone (6 vs. 1 month, P
≤ 0.0001). However, the authors found no significant
difference in median survival between patients receiv-
ing chemotherapy alone and patients given local treat-
ment in addition to chemotherapy, although it should
be noted that the latter group contained only three
patients. Overall, median survival was just 3 months
(range 0.5-50 months). Therefore, a standard treatment
for unresectable SCC of the pancreas has not been
established at yet. Recently, Yachida et al [21] estab-
lished a new cell line (A99) from a primary SCCP
patient. A99 cells were positive for chromogranin A,
NSE. The establishment of this cell line may help in
studying the cell biology of SCCP or for evaluating
novel targeted agents in preclinical models.
Conclusions
The SCCP is a rare type pancreatic cancer and has poor
prognosis; therefore the accurate diagnosis of SCCP is
necessary. Whether the patients had their tumors
resected, the adjuvant chemotherapy should be per-
formed, and cisplatin/etoposide appears to be the pre-
ferred chemotherapy regimen at present.
Table 1 Summary of the clinical data reported cases of small cell carcinoma of the pancreas
Ref. Age Sex Location Treatment Survival
4 42 M Body Symptomatic 1 month
4 67 M Head Symptomatic 1 month
4 62 M Head Symptomatic 2 months
4 54 M Head Symptomatic 2 months
4 73 M Head Symptomatic 1 month
5 45 M Head Symptomatic Not stated
5 75 M Head Symptomatic Not stated
6 27-60 3F/3M Head Surgery and Chemoradiotherapy 9-173 months
7 50 F Tail Symptomatic 2 weeks
8 66 M Head Symptomatic, polychemotherapy followed by CDDP VP-16 2 week
12 69 F Head Surgery and CDDP, VP-16 6 months
13 62 M Head CDDP, Doxorubicin, VP-16 2 month
18 54 M Head Polychemotherapy followed by CDDP, VP-16 50 month
19 64 F Not stated Carboplatin, etoposide 56 months
19 69 M Not stated Carboplatin, etoposide 14 months
19 62 M Not stated Carboplatin, etoposide 9 months
19 69 M Not stated Carboplatin, etoposide 18 months
20 74 M Tail Gemcitabin, PEGylated octreotide, 5-FU 8 months
CDDP: cis-dichlorodiammine platinum; VP-16: etoposide; 5-FU: 5-fluorouracil
Wang et al. World Journal of Surgical Oncology 2012, 10:32
http://www.wjso.com/content/10/1/32
Page 3 of 4Consent
Written informed consent was obtained from the
patients for publication of this report. A copy of the
written consent is available for review with the Editor-
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